The TRIM Study

Better outcomes, less medication.

Our peer-reviewed research shows you don't need high GLP-1 doses to achieve lasting weight loss.

TRIM study presented at ECO 2025

Can you achieve the same weight loss with less medication?

Most GLP-1 programs escalate to the maximum dose as fast as the label allows. The TRIM study asked a different question: what happens when you pair low-dose GLP-1s with intensive behavioral coaching, personalized titration, and structured tapering? The short answer: comparable outcomes to the largest randomized controlled trials, with less than half the medication.

Real-world outcomes from 2,694 participants

Seier et al., Diabetes, Obesity and Metabolism, 2025

16.7%
Average weight loss

Over 64 weeks, across all BMI classes

~1.08mg
Average weekly dose

Less than half the standard maximum

78.5%
Tapered or stopped GLP-1s

No average weight regain post-taper

98%
Clinically significant

85.3% lost 10%+. 51% lost 15%+.

How TRIM compares to the largest GLP-1 trials

The STEP program is the gold standard for semaglutide outcomes. TRIM achieved comparable weight loss with a fundamentally different approach.

STEP trials (RCT)
15-16% weight loss
2.4 mg/week

86-90% of participants titrated to maximum dose

No structured tapering

Participants stayed on maximum dose throughout the trial

In-clinic lifestyle support

Standard counseling alongside medication

TRIM study (Embla, real-world)
16.7% weight loss
~1.08 mg/week

Less than half the standard maximum. Only 28.8% titrated above 1 mg

78.5% tapered or stopped

Structured tapering from month 16. No average weight regain.

Intensive behavioral coaching

1:1 coaching via app. CBT, ACT, personalized nutrition, and exercise.

Dr. Henrik Gudbergsen, Chief Medical Officer at Embla

"This study showed us that combining intensive behavioral intervention with an eHealth weight management clinic can reproduce the results we see in clinical trials, but with far less medication."

Dr. Henrik Gudbergsen, MD, PhD, Chief Medical Officer, Embla

Hear it from the researchers

Henrik Gudbergsen (Chief Medical Officer) and Søren Seier (lead author) walk through the TRIM study findings and what they mean for the future of weight care.

What this means for your benefits strategy

The TRIM study isn't just clinical research. It's the evidence base behind every Embla program.

Lower pharmacy spend

55% less GLP-1 medication per member. Not because treatment is rationed, but because behavioral coaching reduces the dose members need to maintain their results.

Outcomes that last

78.5% of members tapered or stopped GLP-1s with no average weight regain. The behavioral foundation means results don't depend on indefinite prescribing.

Predictable cost trajectory

Treat-to-target dosing and structured tapering means medication costs go down over time, not up. Every member has a deprescribing plan from day one.

Featured on the GLP-1 Hub

The science of tapering off GLP-1s

Henrik Gudbergsen joins Ana Reisdorf on the GLP-1 Hub podcast to discuss personalized dosing, what Embla's data shows about tapering, and why behavioral support changes the medication equation.

"Medication opens the door, but the engagement in lifestyle and the habits that we work with are what keeps the weight off over time."

Ready to offer evidence-based GLP-1 care?

Let's discuss how Embla's research-backed model fits into your benefits strategy.

All medical services are provided by a licensed medical practice independent of Embla Health US Inc. Embla Health US Inc. is not a medical provider and does not practice medicine. Medical services are provided by licensed healthcare professionals who are licensed to practice in the patient's state. Availability of services may vary by jurisdiction. A licensed clinician will independently evaluate eligibility for any medical treatment. Not all patients will qualify. Treatment decisions are made solely by the patient's licensed provider. Medical consultations are conducted via telehealth by state-licensed providers. Telehealth services may not be available in all states and are subject to applicable state telehealth regulations.